Celldex Therapeutics Announces Dosing Of First Patient In Phase 1/2 Clinical Trial Of Its CDX-1401 Cancer Vaccine Candidate

Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced that the first patient has been dosed in a Phase 1/2 study of its vaccine candidate, CDX-1401, in patients with malignant solid tumors that express NY-ESO-1.